In Reply We thank our colleagues for their comments on our cohort study, the Imperial Prostate 1 Prostate Cancer Screening Trial Using Imaging (IP1-PROSTAGRAM).1 To our knowledge, this study provides the first outcomes for the use of a short magnetic resonance imaging (MRI) as a population-based screening test for prostate cancer, and certainly more research is required before screening MRI is recommended. Other studies, such as ReIMAGINE2 and the GÖTEBORG prostate cancer screening 2 randomized clinical trial,3 will provide further evidence. We would like to provide a point-by-point response to address other issues raised.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Eldred-Evans D, Ahmed HU. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study—Reply. JAMA Oncol. 2021;7(10):1575–1576. doi:10.1001/jamaoncol.2021.2967
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.